BioCentury | Feb 29, 2016
Clinical News

Dapivirine Vaginal Ring: Phase III data

...25 mg dapivirine reduced the incidence of HIV infection by 30.7% vs. placebo (p=0.0401). The Dapivirine...
...Dapivirine Vaginal Ring Business: Infectious Molecular target: NA Description: Once-monthly vaginal ring containing 25 mg dapivirine...
BioCentury | Feb 29, 2016
Clinical News

Dapivirine Vaginal Ring: Phase III data

...25 mg dapivirine reduced the incidence of HIV infection by 27% vs. placebo (p=0.046). The Dapivirine...
...Dapivirine Vaginal Ring Business: Infectious Molecular target: NA Description: Once-monthly vaginal ring containing 25 mg dapivirine...
BioCentury | May 12, 2014
Company News

J&J, International Partnership for Microbicides deal

...Johnson's Janssen R&D Ireland unit granted the not-for-profit exclusive, worldwide rights to develop and commercialize dapivirine...
...dianilinopyrimidine derivative in developing countries under the original deal. A monthly sustained-release vaginal ring containing dapivirine...
...The partners declined to disclose financial terms. IPM said the public health need for the dapivirine...
BioCentury | Jun 14, 2010
Clinical News

Dapivirine: Phase I/II started

...releases 25 mg dapivirine over 28 days. The non-profit organization has a royalty-free license for dapivirine...
...Ltd. unit (see BioCentury, April 5, 2004). Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Dapivirine...
BioCentury | May 21, 2009
Targets & Mechanisms

Circle of protection against HIV

...immune system." IPM has completed Phase I studies of gel-based and vaginal ring-based formulations of dapivirine...
...said IPM plans to start multiple Phase I/II studies of both formulations later this year. Dapivirine...
BioCentury | Apr 23, 2009
Cover Story

Topical ideas for HIV

...company's lead products are gel-based and vaginal ring formulations of the non-nucleotide reverse transcriptase inhibitor dapivirine...
BioCentury | Feb 14, 2008
Cover Story

New roadblock to HIV infection

...HIV Phase II CONRAD UC-781 ARV carbomer gel NNRTI targeting HIV Phase I IPM Dapivirine (TMC120...
BioCentury | Apr 5, 2004
Company News

J&J, International Partnership for Microbicides deal

...subsidiary Tibotec Pharmaceuticals Ltd. (Mechelen, Belgium) to develop, manufacture and distribute in "resource poor countries" TMC120...
...transcriptase inhibitor to protect women from HIV infection. IPM will also develop other formulations of TMC120...
BioCentury | Feb 12, 2001
Clinical News

TMC120: Phase I/II

...in a Phase I/II trial of 43 patients with HIV, 50 or 100 mg of TMC120...
...p<0.001 versus placebo at both doses). The company also reported in vitro data showing that TMC120...
...Retroviruses and Opportunistic Infections in Chicago. Tibotec Group NV , Mechelen, Belgium Product: TMC120 ( R147681...
BioCentury | Feb 9, 2001
Clinical News

Tibotec Phase II HIV data

...said that in a double-blind, placebo-controlled Phase II study in 43 treatment-naive HIV patients, its TMC120...
...mean 1.51 log reduction in viral load after one week. Patients received 100 mg of TMC120...
Items per page:
1 - 10 of 10